HOME HELP CONTACT US SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by DEMOULIN, A. Articles by LEGROS, J. J. Search for Related Content PubMed Articles by DEMOULIN, A. Articles by LEGROS, J. J.

*Howard Florey Institute of Experimental Physiology and Medicine, Melbourne, Victoria, Australia and Radioimmunoassay Laboratory, University of Liège, B-4000 Liège, Belgium

(Received 8 July 1976)

The nonapeptide, arginine-vasotocin (AVT, mol. wt 1050) present in the pineal gland of mammals, including man (Milcu, Pavel & Neacsu, 1963; Pavel, 1973; Legros, Louis, Demoulin & Franchimont, 1976) has been shown to reduce gonadotrophin secretion in vivo (Pavel & Petrescu, 1966; Cheesman & Fariss, 1970; Vaughan, Vaughan & Reiter, 1975). When injected into the third ventricle in doses of 0·5 µu. (1 pg), AVT has been shown to inhibit compensatory ovarian hypertrophy in the mouse (Pavel, Petrescu & Vicoleanu, 1973). However, when used in pharmacological doses (2–50 µg) AVT did not inhibit pregnant mare serum-human chorionic gonadotrophin-induced ovulation response in the mouse (Cheesman & Forsham, 1974). Comparable doses were also found to be ineffective in altering the secretion of gonadotrophins from rat anterior hemipituitary